Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

105 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Emerging drugs for acute lymphocytic leukemia.
Mathisen MS, Kantarjian HM, Jabbour EJ. Mathisen MS, et al. Among authors: jabbour ej. Expert Opin Emerg Drugs. 2014 Mar;19(1):37-50. doi: 10.1517/14728214.2014.872629. Epub 2013 Dec 20. Expert Opin Emerg Drugs. 2014. PMID: 24354521 Review.
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Saba R, et al. Among authors: jabbour e. Cancer. 2005 Jun 15;103(12):2551-7. doi: 10.1002/cncr.21086. Cancer. 2005. PMID: 15861412 Clinical Trial.
New agents in myelodysplastic syndromes.
Jabbour EJ, Giles FJ. Jabbour EJ, et al. Curr Hematol Rep. 2005 May;4(3):191-9. Curr Hematol Rep. 2005. PMID: 15865871 Review.
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. Jabbour E, et al. Cancer. 2005 Aug 1;104(3):541-6. doi: 10.1002/cncr.21186. Cancer. 2005. PMID: 15977212
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Oki Y, et al. Among authors: jabbour e. Blood. 2006 Feb 1;107(3):880-4. doi: 10.1182/blood-2005-06-2450. Epub 2005 Aug 25. Blood. 2006. PMID: 16123215
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Jabbour E, et al. Blood. 2006 Jan 15;107(2):480-2. doi: 10.1182/blood-2005-05-1816. Epub 2005 Sep 29. Blood. 2006. PMID: 16195326
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Giles F, et al. Among authors: jabbour e. Clin Cancer Res. 2005 Nov 1;11(21):7817-24. doi: 10.1158/1078-0432.CCR-05-1070. Clin Cancer Res. 2005. PMID: 16278404 Clinical Trial.
Adult acute lymphoblastic leukemia.
Jabbour EJ, Faderl S, Kantarjian HM. Jabbour EJ, et al. Mayo Clin Proc. 2005 Nov;80(11):1517-27. doi: 10.4065/80.11.1517. Mayo Clin Proc. 2005. PMID: 16295033 Review.
105 results
Jump to page
Feedback